Veru Posts Mixed Q4 Results

by Shivani Kumaresan, Benzinga Staff Writer

December 2, 2021 11:08 AM | 1 min read |

Veru Inc VERU reported fourth-quarter FY21 sales growth of 32.8% year-on-year, to $15.65 million, missing the analyst consensus of $18.17 million.
FC2 prescription net revenues climbed 55% Y/Y to $13.6 million.
Gross profit rose 29% to $12.3 million, while the margin contracted 200 basis points Y/Y to 79%.
The operating loss for the quarter narrowed to $(1.9) million.
The company held $122.4 million in cash and equivalents as of September 30, 2021.
EPS loss of $(0.05) beat the analyst consensus of $(0.09).
Price Action: VERU shares traded lower by 2.32% at $6.75 on the last check Thursday.